European Union - English - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - pigs - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - clostridium haemolyticum; clostridium perfringens type b toxoid; clostridium perfringens type c toxoid; clostridium chauvoei whole cell culture; clostridium novyi tybe b toxiod and inactivated cells; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; thiomersal; aluminium (adjuvant) - misc. vaccines or anti sera - clostridium haemolyticum vaccine-toxoid active 21.2 tcp u/ml; clostridium perfringens type b toxoid vaccine-toxoid active 30.6 tcp u/ml; clostridium perfringens type c toxoid vaccine-toxoid active 15.3 tcp u/ml; clostridium chauvoei whole cell culture vaccine-microbial active 30.0 %ferm/ml; clostridium novyi tybe b toxiod and inactivated cells vaccine-toxiod active 5.95 tcp u/ml; clostridium perfringens type d toxoid vaccine-toxoid active 55.3 tcp u/ml; clostridium septicum - toxoid vaccine-toxoid active 6.4 tcp u/ml; clostridium tetani - toxoid vaccine-toxoid active 3.0 lf u/ml; thiomersal mercury other 0.15 mg/ml; aluminium (adjuvant) mineral-aluminium other 0.0 mg/ml - immunotherapy - cattle | lamb | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | hei - black disease | blackleg | dysentery | enterotoxaemia (pulpy kidney) | haemorrhagic enterotoxaemia | malignant oedema | post parturient gangrene | swelled head | tetanus | tick fever - bovine babesiosis | babesia bigemina | babesia bovis | clostridium perfringens type d | red water | redwater | tetanus vaccination

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - bovine rotavirus (ncdv); clostridium perfringens type c toxoid; escherichia coli k99 pilus antigens; clostridium perfringens type d toxoid; bovine coronavirus (inactivated) - misc. vaccines or anti sera - bovine rotavirus (ncdv) biological-virus active 1.0 rp; clostridium perfringens type c toxoid vaccine-toxoid active 10.0 iu/ml; escherichia coli k99 pilus antigens vaccine-microbial active 1.0 rp; clostridium perfringens type d toxoid vaccine-toxoid active 2.0 iu/ml; bovine coronavirus (inactivated) vaccine-viral active 1.0 rp - immunotherapy - cow | healthy pregnant heifer | bovine | female cattle - bovine rotaviruses | neonatal calf diarrhea | neonatal enterotoxemia | raise colostral antibodies | against bovine rotavirus and | coronavirus | enterotoxigenic e.coli pilus | g6 and g10 | type k99

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - pigs - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b.- to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

European Union - English - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - immunologicals for suidae - pigs - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - reduction of neonatal enterotoxicosis of piglets, caused by e. coli strains, expressing the adhesins f4ab, f4ac, f4ad, f5, f6 and f41, during the first days of life.

European Union - English - EMA (European Medicines Agency)

intervet international bv - clostridium perfringens type c / escherichia coli f4ab / e. coli f4ac / e. coli f5 / e. coli f6 / e. coli lt - immunologicals - pigs - for the passive immunisation of progeny by active immunisation of sows and gilts to reduce mortality and clinical signs during the first days of life, caused by those escherichia coli strains which express the adhesins f4ab (k88ab), f4ac (k88ac), f5 (k99) or f6 (987p) and caused by clostridium perfringens type c.,

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios hipra s.a. - f4ab fimbrial adhesin of e.coli; f4ac fimbrial adhesin of e.coli; f5 fimbrial adhesin of e.coli; f6 fimbrial adhesin of e. coli; lt enterotoxoid of e. coli; clostridium perfringens, type c toxoid; clostridium novyi, type b toxoid - suspension for injection - . - escherichia + clostridium - pigs - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

intervet international bv - protein do (non-toxic deletion derivative of pasteurella multocida dermonecrotic toxin), inactivated bordetella bronchiseptica cells - immunologicals for suidae - pigs (gilts and sows) - for the reduction of clinical signs of progressive atrophic rhinitis in piglets by passive oral immunisation with colostrum from dams actively immunised with the vaccine.

United States - English - NLM (National Library of Medicine)

slv pharmaceuticals llc dba aum pharmaceuticals - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - neonatal fe rx prenatal vitamin with ferronyl iron vitamin is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.